Phase 3 EPCORE DLBCL-2 trial met primary endpoint; epcoritamab + R-CHOP reduced risk of progression or death by 51% vs R-CHOP alone in newly diagnosed DLBCL patients with IPI 2-5. Safety consistent. Companies to engage regulators.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
